CASR

Extracellular calcium-sensing receptor · P41180 · CASR on Sugi Atlas →

56,100 patent compounds predicted against CASR, 29,287 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL125597	1.00	20/20
SCHEMBL126635	1.00	20/20
SCHEMBL126936	1.00	20/20
SCHEMBL127759	1.00	20/20
SCHEMBL128503	1.00	20/20
SCHEMBL128778	1.00	20/20
SCHEMBL129294	1.00	20/20
SCHEMBL172222	1.00	20/20
Encaleret (SCHEMBL482046)	1.00	20/20
Encaleret (SCHEMBL482047)	1.00	20/20
Hydrochloric Acid (SCHEMBL128115)	0.98	20/20
Hydrochloric Acid (SCHEMBL127569)	0.98	20/20
Hydrochloric Acid (SCHEMBL128210)	0.98	20/20
Hydrochloric Acid (SCHEMBL125409)	0.98	20/20
Hydrochloric Acid (SCHEMBL128247)	0.98	20/20
SCHEMBL128241	0.92	20/20
SCHEMBL126652	0.92	20/20
SCHEMBL127915	0.92	20/20
SCHEMBL125231	0.90	20/20
SCHEMBL126474	0.89	20/20

Clinical trials — most relevant to CASR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid	PHASE4	COMPLETED
Novel Combination Therapy for Osteoporosis in Men	PHASE4	ACTIVE_NOT_RECRUITING
Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism	PHASE4	COMPLETED
The Effect of Protein on Calcium Absorption and Gastric Acid Production	PHASE4	COMPLETED
Next Generation ORS: Comparing ORS With Calcium vs Standard ORS in Reducing Severity of Acute Watery Diarrhea	PHASE2/PHASE3	COMPLETED
Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.	PHASE3	COMPLETED
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism	PHASE2	COMPLETED
Calcium Channel Blockade in Primary Aldosteronism	PHASE2	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment	PHASE2	UNKNOWN
Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets	PHASE1	COMPLETED
Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism	nan	UNKNOWN
Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment	nan	COMPLETED
Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome	nan	UNKNOWN
The Effect of Cinacalcet on Gastric Acid Output in Healthy Subjects	nan	COMPLETED
Evaluation of Microbial and Endocrinological Parameters in Dialysis Patients With Sepsis	nan	RECRUITING
Lipid and Glycogen Metabolism in Patients With Impaired Glucose Tolerance and Calcium Sensing Receptor Mutations	nan	UNKNOWN
Diurnal Variation in Markers of Mineral and Bone Disease in Chronic Kidney Disease	nan	COMPLETED
New Transporting Solution in Parathyroid Allotransplantation	nan	UNKNOWN
Hypoparathyroidism in Denmark	nan	COMPLETED
Characterization of Patients With Non-surgical Hypoparathyroidism and Pseudohypoparathyroidism	nan	UNKNOWN
University of Wisconsin Solution Versus New Parathyroid Transport Solution for Parathyroid Allotransplantation	nan	UNKNOWN
Prognostic Value of Vitamin D Levels in Egyptian Females With Breast Cancer	nan	UNKNOWN
Theranova Dialyzer and Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD)	nan	UNKNOWN
The Bone-parathyroid Crosstalk in Primary Hyperparathyroidism	nan	UNKNOWN
Evaluation of Prevalence, Molecular and Genetic Backgrounds of Calcium-Based Stones Among Patients With Renal Calcular Disease in Mansoura Urology and Nephrology Center	nan	COMPLETED
Ratio of Dietary Calcium to Magnesium on Cardiovascular Risk	nan	UNKNOWN
Arterial Stiffness and Decreased Bone Buffering Capacity in Hemodialysis Patients	nan	COMPLETED
Comparative Effects of Doxercalciferol and Calcitriol on Secondary Hyperparathyroidism in ESRD	nan	NOT_YET_RECRUITING
QoL and Cognitive Function in Patients With Hypoparathyroidism	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CASR binder may also engage these)

Protein	Name	Similarity
P48442	—	1.000	P48442 →
Q9QY96	—	1.000	Q9QY96 →
O62714	—	1.000	O62714 →
P35384	—	1.000	P35384 →
O70410	—	1.000	O70410 →
GRM1	Metabotropic glutamate receptor 1	0.995	landscape →
Q9PW88	—	0.994	Q9PW88 →
Q09630	—	0.994	Q09630 →
GRM5	Metabotropic glutamate receptor 5	0.994	landscape →
A3QNZ9	—	0.993	A3QNZ9 →
Q5U9X3	—	0.993	Q5U9X3 →
TAS1R2	Taste receptor type 1 member 2	0.993	landscape →
Q3UVX5	—	0.992	Q3UVX5 →
A3QNZ8	—	0.992	A3QNZ8 →
E1BPQ3	—	0.992	E1BPQ3 →
Q80T41	—	0.992	Q80T41 →
Q5T6X5	—	0.992	Q5T6X5 →
A3QP00	—	0.991	A3QP00 →
P97772	—	0.991	P97772 →
A3QP07	—	0.990	A3QP07 →
P31424	—	0.990	P31424 →
G5ECB2	—	0.990	G5ECB2 →
Q925I4	—	0.990	Q925I4 →
Q5RAL3	—	0.989	Q5RAL3 →
A3QP01	—	0.988	A3QP01 →
P91685	—	0.988	P91685 →
P23385	—	0.988	P23385 →
Q70VB1	—	0.988	Q70VB1 →
GRM3	Metabotropic glutamate receptor 3	0.988	landscape →
Q49HI0	—	0.988	Q49HI0 →